This grant is for the purpose of advancing HIV cure strategies by addressing viral persistence in people living with HIV. It supports coordinated basic, clinical, and applied research aimed at achieving sustained viral remission or eradication of HIV infection. While clinical research is required, the grant explicitly excludes clinical trials. Applications must involve a private sector entity to facilitate rapid translation of discoveries into therapeutic development. The research should be milestone-based, focusing on characterizing HIV-1 reservoirs, understanding post-treatment control of viral rebound, and identifying/testing therapeutic strategies to control, eradicate, or permanently inactivate rebound-competent HIV after antiretroviral therapy discontinuation.
Opportunity ID: 327673
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AI-20-035 |
| Funding Opportunity Title: | Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.242 — Mental Health Research Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 15, 2020 |
| Last Updated Date: | Jun 15, 2020 |
| Original Closing Date for Applications: | Dec 07, 2020 |
| Current Closing Date for Applications: | Dec 07, 2020 |
| Archive Date: | Jan 12, 2021 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $3,500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Native American tribal governments (Federally recognized) Special district governments County governments Public and State controlled institutions of higher education Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) Private institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to address the problem of HIV persistence in people living with HIV treated with suppressive antiretroviral drug regimens. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into therapeutic development and testing. Collaboratory research should be milestone-based and should be focused on specific innovative approaches to characterize and quantify persistent HIV-1 reservoirs and/or understand and predict post-treatment control of viral rebound, identify and test therapeutic strategies to control viral rebound after discontinuation of antiretroviral therapy, and identify and test strategies to eradicate or permanently inactivate rebound-competent HIV. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-035.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00262212 | Nov 06, 2020 | Dec 07, 2020 | View |
Package 1
Mandatory forms
327673 RR_SF424_2_0-2.0.pdf
327673 PHS398_CoverPageSupplement_5_0-5.0.pdf
327673 RR_OtherProjectInfo_1_4-1.4.pdf
327673 PerformanceSite_2_0-2.0.pdf
327673 RR_KeyPersonExpanded_2_0-2.0.pdf
327673 RR_Budget_1_4-1.4.pdf
327673 PHS398_ResearchPlan_4_0-4.0.pdf
327673 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
327673 RR_SubawardBudget30_1_4-1.4.pdf
327673 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
